ArticleCanadian journal of gastroenterology = Journal canadien de gastroenterologie2009
Renal effects of long-term treatment with 5-aminosalicylic acid.
Article in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Renal manifestations in inflammatory bowel disease: a systematic review.Journal of gastroenterology · 2022Pooled it
- Extraintestinal Manifestations of Inflammatory Bowel Disease: A Focus on Kidney Complications.International journal of molecular sciences · 2026Review
- Artificial intelligence-driven strategies for managing renal and urinary complications in inflammatory bowel disease.World journal of nephrology · 2025Article
- Monitoring for 5-aminosalicylate nephrotoxicity in adults with inflammatory bowel disease: prognostic model development and validation using data from the Clinical Practice Research Datalink.BMJ open gastroenterology · 2025Article
- Drug-induced Interstitial Nephritis in a Patient with Ulcerative Colitis Treated with 5-Aminosalicylic Acid.Internal medicine (Tokyo, Japan) · 2024Article
- Cirsimaritin Alleviates Dextran Sodium Sulfate-Induced Acute Colitis in Experimental Animals: A Therapeutic Approach for Inflammatory Bowel Disease.Preventive nutrition and food science · 2024Article
- Renal and Urological Disorders Associated With Inflammatory Bowel Disease.Inflammatory bowel diseases · 2023Review
- Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study.Inflammatory intestinal diseases · 2022Article
- Protective antioxidative and anti-inflammatory actions of β-caryophyllene against sulfasalazine-induced nephrotoxicity in rat.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Diosmetin has therapeutic efficacy in colitis regulating gut microbiota, inflammation, and oxidative stress via the circ-Sirt1/Sirt1 axis.Acta pharmacologica Sinica · 2022Article
- A Case Report and Literature Review of Mesalazine-Induced Kidney Injury in a Pediatric Patient With Ulcerative Colitis.Frontiers in pediatrics · 2022Article
- Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy.World journal of stem cells · 2020Review
- Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease.Intestinal research · 2020Review
- Effects of herb-partitioned moxibustion for ulcerative colitis: A protocol for systematic review and meta-analysis.Medicine · 2020Article
- Article
- [Treatment of rheumatic disease with renal insufficiency].Der Orthopade · 2019Review
- Inflammatory bowel disease in patients undergoing renal biopsies.Clinical kidney journal · 2019Article
- Interstitial Nephritis in a Patient with Inflammatory Bowel Disease.Case reports in nephrology · 2016Article
- [Dosage and toxicity of antirheumatic drugs in renal insufficiency].Zeitschrift fur Rheumatologie · 2015Review
- Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.Gastroenterology & hepatology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA number of case reports link the use of 5-aminosalicylic acid (5-ASA) to interstitial nephritis in patients with inflammatory bowel disease (IBD).
objectiveTo investigate whether the long-term use of 5-ASA has harmful effects on renal function in patients with IBD.
methodsA retrospective analysis of 171 consecutive outpatients with Crohn's disease or ulcerative colitis was conducted. Serum creatinine levels and body weight were measured before and after treatment to calculate the creatinine clearance (CrCl) rate.
resultsIn 171 patients (93 women, 78 men), the mean (+/- SD) dose of 5-ASA was 3.65+/-0.85 g/day with a cumulative dose of 11+/-7.7 kg over an interval of 8.4+/-5.9 years. Serum creatinine concentrations increased from 76.8 micromol/L to 88.7 micromol/L (n=171; P<0.0001) and the CrCl rate fell significantly from 104.6 mL/min to 93.1 mL/min (n=81; P<0.0001). There was one case of interstitial nephritis reported. Treatment groups included mesalamine (74.3%), sulfasalazine (15.2%) and combination (sulfalsalazine/mesalamine [10.5%]) with treatment durations of 7.2+/-4.5, 12.3+/-8.7 and 11.2+/-6.7 years, respectively. The duration of treatment was the most important covariate for change in CrCl and when analyzed by treatment group, those treated with sulfasazine had a strong correlation (r=-0.54, P=0.0145), while nonsignificant in the mesalamine group (r=0.06, P=0.7017). The decline in CrCl was negatively correlated with the pretreatment CrCl rate (r=-0.34; P=0.0024) and positively correlated with the mean daily dose of 5-ASA (r=0.32; P=0.0034).
conclusionThe present study is the first to demonstrate a significant dose- and treatment duration-dependant decline in CrCl. The risks need to be further evaluated because 5-ASA is widely used for long-term maintenance therapy in patients with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.